Ultra-Rapid Profiling and Drug Screening for Treatment Selection in Patients With Relapsed or Recurrent Rare Brain Tumors

Part of paid clinical trials in Washington D.C., District of Columbia.

Sponsor
Adriana Fonseca
Study ID
NCT07851636
Status
Recruiting
Apply to this trial

Conditions

  • BCOR ITD Sarcoma
  • CNS Sarcoma
  • FOXR2-activated
  • Mesenchymal Tumor
  • PLAG-altered Tumors
  • Rare CNS Tumor

Eligibility Criteria

Sex
ALL
Age
N/A - 45 Years
Healthy Volunteers
Not accepted

Interventions

  • Personalized Treatment Recommendation — OTHER
    Specialized Treatment Plan of up to four FDA approved drugs based on participant's screening results will be assigned by Rare Brain Tumor specialized tumor board. Recommendations will be provided and to primary physician.

Study Details

The current study will use a new treatment approach based on the molecular characteristics of each participant's tumor. The study will test the feasibility in of performing real-time drug screening on tissue taken during surgery in patients with relapsed ultra rare brain tumors (BCOR -altered, MN1-altered, CNS Sarcomas, other rare brain tumors) and of having a specialized tumor board assign a treatment plan based on the results of the drug screening and genomic sequencing. The aim of this trial is to allow every child and young adult with relapsed ultra rare brain tumors to receive the most effective and least toxic therapies currently available and will pave the way for improved understanding and treatment of these tumors in the future. Moreover, if successful, it could serve as a paradigm for personalized medicine programs for other types of cancer.

Key Dates

First listed
Oct 1, 2026
Start date
Oct 31, 2026
Status verified
Oct 2026
Primary completion
Jan 31, 2032
Completion
Oct 31, 2032

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
OTHER

Arms

  • Experimental: Personalized Treatment Recommendation
    Participants will be provided a treatment recommendation by the tumor board within 28 days from tissue acquisition. Based on the results of the real-time, High-throuput drug screeningRNA sequencing (RNAseq), whole genome sequencing (WGS), and clinical details of each subject's tumor.

Primary Outcome Measure

Number of participants for whom a treatment recommendations are completed within 28 calendar days from tissue collection. [ Time Frame: Up to 28 calendar days ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Children's National HospitalWashington D.C.District of Columbia20010-

Find similar trials in Washington D.C., DC

By research site
Children's National Hospital· Washington D.C., DC

Related Studies